BRAF (V600E)
GR6/Rabbit/Monoclonal
Gene Bio Solution BRAF (V600E) Antibody. Gene bio solution’s rabbit recombinant monoclonal antibody specifically recognizes the protein encoded by the BRAF (V600E) mutation. The V600E mutation leads to the production of a constitutively active BRAF protein, resulting in uncontrolled cell growth and division. Identifying the presence of this mutation is crucial for diagnosing and guiding the treatment of melanoma, colorectal cancer, and certain types of thyroid cancer, lung cancer, and Hairy cell leukemia.
The BRAF gene encodes a protein that is part of the RAS-RAF-MEK-ERK signaling pathway, which regulates cell division and proliferation. The V600E mutation in the BRAF gene leads to the production of a constitutively active BRAF protein, resulting in uncontrolled cell growth and division. Identifying the presence of this mutation is crucial for diagnosing and guiding the treatment of certain cancers. The BRAF (V600E) antibody is used in immunohistochemistry to detect the presence of a specific mutation in the BRAF gene known as V600E. This mutation is commonly associated with various cancers, including melanoma, colorectal cancer, and certain types of thyroid cancer, lung cancer, and Hairy cell leukemia. The BRAF (V600E) antibody specifically binds to the mutated BRAF protein, allowing pathologists to detect the mutation in cancer tissue. Immunohistochemistry using this antibody is often employed in the evaluation of tumor specimens to aid in the diagnosis and classification of cancers.
In BRAF (V600E) melanoma, the upstream RAS kinase activity is not required for cellular division, indicating BRAF (V600E) as a distinct and defining driver of malignant disease progression in melanoma. Although BRAF (V600E) mutation in malignant melanoma is prevalent, the BRAF gene encoding the V600E mutant has been identified in other solid tumors such as thyroid cancer, bladder urothelial cancer, chronic lymphocytic leukemia, colorectal cancer, glioblastoma multiforme (GBM), head and neck squamous cell carcinoma, renal papillary cell carcinoma, hepatocellular carcinoma, lung adenocarcinoma, and lymphoma.
The BRAF (V600E) Gene bio solution-Antibody GR6 recognizes the mutated valine V600 changed to the highly polar and acidic glutamate E sidechain -CH2-CH2-COO– typically physiologically ionized. Antibody clone GR6 represents a new and favorable option in the detection of BRAF (V600E) in malignant melanoma and other malignancies.
